keyword
https://read.qxmd.com/read/38245327/pathogenetic-treatments-for-diabetic-peripheral-neuropathy
#1
JOURNAL ARTICLE
Dan Ziegler
Diabetic peripheral neuropathy (DPN) is found in around one third of people with diabetes, but remains inadequately diagnosed and treated. Its management includes three cornerstones: 1) causal treatment with lifestyle modification, intensive diabetes therapy aimed at near-normoglycemia, and multifactorial cardiovascular risk intervention, 2) pathogenesis-oriented pharmacotherapy, and 3) symptomatic pain relief. Since symptomatic analgesic monotherapy only relieves the pain without targeting the underlying neuropathy and both has limited efficacy and is associated with adverse events, there is an unmet need for additional approaches derived from the pathogenetic concepts of DPN...
December 2023: Diabetes Research and Clinical Practice
https://read.qxmd.com/read/38112729/protective-effects-of-benfotiamine-on-cyfluthrin-induced-testicular-damage-and-sperm-characteristics-during-the-prepubertal-period
#2
JOURNAL ARTICLE
Gözde Parlak, Neriman Çolakoğlu
Cyfluthrin, a widely used synthetic pyrethroid insecticide, poses potential risks to both human health and the environment due to its extensive application in residential, agricultural, and outdoor settings. Conversely, benfotiamine, a fat-soluble derivative of vitamin B1, offers versatile therapeutic potential. This experimental study aimed to investigate the impact of cyfluthrin exposure during the prepubertal period on sperm characteristics and testicular tissue integrity in male rats, as well as to assess the protective effects of benfotiamine...
December 19, 2023: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/38043777/harnessing-the-neuroprotective-effect-of-oral-administration-of-benfotiamine-in-mptp-induced-parkinson-s-disease-in-rats
#3
JOURNAL ARTICLE
Bushra Bashir, Swati Mittal, A Muthukumar, Sukriti Vishwas, Narendra Kumar Pandey, Monica Gulati, Gaurav Gupta, Muralikrishnan Dhanasekaran, Puneet Kumar, Harish Dureja, Francisco Veiga, Ana Claudia Paiva-Santos, Jon Adams, Kamal Dua, Sachin Kumar Singh
The study was performed to evaluate the neuroprotective effects of Benfotiamine (BFT) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD) in rats. The rats were given daily doses of BFT (100mg/kg, 200mg/kg) through oral administration for 42 days. The rats were given a single bilateral dosage of MPTP (0.1 mg/nostril) intranasally once before the drug treatment to induce PD. On day 42, the animals were subjected to various behavioral paradigms. Post-treatment with BFT for 42 days significantly improved the motor and nonmotor fluctuations of MPTP...
December 1, 2023: European Journal of Pharmacology
https://read.qxmd.com/read/38034619/thiamine-and-benfotiamine-focus-on-their-therapeutic-potential
#4
REVIEW
Iva Bozic, Irena Lavrnja
Thiamine, also known as vitamin B1, is an essential nutrient that plays a crucial role in energy metabolism and overall health. It is a water-soluble vitamin that plays an important role in the conversion of carbohydrates into energy in the body. Thiamine is essential for the proper functioning of the nervous system, heart and muscles. Thiamine deficiency is a life-threatening disease that leads to various disorders and lesions in the nerves and brain, at least in vertebrates. Several thiamine precursors with higher bioavailability have been developed to compensate for thiamine deficiency, including benfotiamine...
November 2023: Heliyon
https://read.qxmd.com/read/37907963/multimodal-treatment-including-extracorporeal-shock-wave-therapy-for-refractory-chronic-tension-type-headache-a-case-report
#5
JOURNAL ARTICLE
Toru Takekawa, Toshifumi Chino, Naoki Yamada, Shu Watanabe, Masahiro Abo, Renpei Sengoku
BACKGROUND: Few reports have described multidisciplinary treatment, including extracorporeal shock wave therapy, for patients with refractory chronic tension-type headache. In this study, we conducted multidisciplinary treatment for a patient with chronic tension-type headache who suffered from chronic headache refractory to treatment. CASE PRESENTATION: The patient was a 45-year-old Japanese male suffering from 20 years of headache. As his headache had worsened recently, he visited a local clinic...
October 31, 2023: Journal of Medical Case Reports
https://read.qxmd.com/read/37886362/editorial-experts-opinion-in-medicine-2022
#6
EDITORIAL
Victoria I Bunik
No abstract text is available yet for this article.
2023: Frontiers in Medicine
https://read.qxmd.com/read/37511056/synthetic-thioesters-of-thiamine-promising-tools-for-slowing-progression-of-neurodegenerative-diseases
#7
REVIEW
Lucien Bettendorff
Thiamine (vitamin B1) is essential for the brain. This is attributed to the coenzyme role of thiamine diphosphate (ThDP) in glucose and energy metabolism. The synthetic thiamine prodrug, the thioester benfotiamine (BFT), has been extensively studied and has beneficial effects both in rodent models of neurodegeneration and in human clinical studies. BFT has no known adverse effects and improves cognitive outcomes in patients with mild Alzheimer's disease. In cell culture and animal models, BFT has antioxidant and anti-inflammatory properties that seem to be mediated by a mechanism independent of the coenzyme function of ThDP...
July 10, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37333039/impaired-thiamine-metabolism-in-amyotrophic-lateral-sclerosis-and-its-potential-treatment-with-benfotiamine-a-case-report-and-a-review-of-the-literature
#8
Richard H Mann
Homogenates of brain tissue from the frontal cortex at autopsy in patients with amyotrophic lateral sclerosis (ALS) showed dramatically reduced levels of the enzyme thiamine pyrophosphatase (TPPase), the enzyme responsible for the conversion of thiamine pyrophosphate (TPP) to thiamine monophosphate (TMP). Additionally, free thiamine (vitamin B1) and TMP levels have been shown to be significantly reduced in the plasma and cerebral spinal fluid (CSF) of patients with ALS. These findings suggest that there is impaired thiamine metabolism in patients with ALS...
June 2023: Curēus
https://read.qxmd.com/read/36286970/-on-the-specific-treatment-of-asthenic-states-focus-on-sulbutiamine
#9
REVIEW
Y V Bykov, R A Bekker
In this article, we try to present the available data regarding the pharmacokinetics and pharmacodynamics of sulbutiamine (Enerion), the mechanisms of its anti-asthenic action. Then we analyze and summarize the available evidence base considering the efficacy and safety of Enerion for the treatment of asthenic syndromes. Then we compare Enerion with some other drugs. The results of our review indicate the high efficacy and safety of sulbutiamine in the treatment of asthenia. Our results also show that Enerion has some clinically relevant advantages over all alternatives we reviewed there...
June 17, 2022: Terapevticheskiĭ Arkhiv
https://read.qxmd.com/read/36275801/pharmacological-thiamine-levels-as-a-therapeutic-approach-in-alzheimer-s-disease
#10
JOURNAL ARTICLE
Gary E Gibson, Howard H Feldman, Sheng Zhang, Sarah A Flowers, José A Luchsinger
of the study.
2022: Frontiers in Medicine
https://read.qxmd.com/read/36008064/effect-of-thiamine-supplementation-on-glycaemic-outcomes-in-adults-with-type-2-diabetes-a-systematic-review-and-meta-analysis
#11
JOURNAL ARTICLE
Arti Muley, Ritin Fernandez, Heidi Green, Prasad Muley
BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have been shown to have thiamine deficiency. Dietary supplementation is an economic strategy to control blood glucose. Objective: To evaluate effectiveness of thiamine supplementation on glycaemic outcomes in patients with T2DM. METHODS: Eligibility criteria: Studies that assessed effect of thiamine supplementation in adults with T2DM which measured glycaemic outcomes-HbA1c, fasting blood glucose (FBG) and/or postprandial blood glucose (PPG) were included...
August 25, 2022: BMJ Open
https://read.qxmd.com/read/35907494/benfotiamine-protects-against-hypothalamic-dysfunction-in-a-stz-induced-model-of-neurodegeneration-in-rats
#12
JOURNAL ARTICLE
Ruan Carlos Macêdo de Moraes, Gabriely Cristina Alves Lima, Camila Aparecida Erreiras Fernandes Cardinali, Alisson Carvalho Gonçalves, Guilherme Vannucchi Portari, Elvira Maria Guerra-Shinohara, Antoine Leboucher, José Donato, André Kleinridders, Andréa da Silva Torrão
The neurodegeneration of Alzheimer's disease (AD) affects not only brain structures associate with cognition early in the progression of the disease, but other areas such as the hypothalamus, a region involved in the control of metabolism and appetite. In this context, we evaluated the effects of benfotiamine (BFT), a vitamin B1 analog that is being proposed as a therapeutical approach for AD-related cognitive alterations, which were induced by intracerebroventricular injection of streptozotocin (STZ). In addition to the already described effect of STZ on cognition, we show that this drug also causes metabolic changes which are linked to changes in hypothalamic insulin signaling and orexigenic and anorexigenic circuitries, as well as a decreased cellular integrated stress response...
October 1, 2022: Life Sciences
https://read.qxmd.com/read/35578055/repurposing-the-natural-compounds-as-potential-therapeutic-agents-for-covid-19-based-on-the-molecular-docking-study-of-the-main-protease-and-the-receptor-binding-domain-of-spike-protein
#13
JOURNAL ARTICLE
Vajiheh Eskandari
Severe acute respiratory syndrome coronavirus (SARS-CoV-2) enters the cell by interacting with the human angiotensin-converting enzyme 2 (ACE2) receptor through the receptor-binding domain (RBD) of spike (S) protein. In the cell, the viral 3-chymotrypsin-like cysteine protease (3CLpro) enzyme is essential for its life cycle and controls coronavirus replication. Therefore, the S-RBD and 3CLpro are hot targets for drug discovery against SARS-CoV-2. This study was to identify repurposing drugs using in silico screening, docking, and molecular dynamics simulation...
May 16, 2022: Journal of Molecular Modeling
https://read.qxmd.com/read/35535731/therapeutic-potential-of-vitamin-b-1-derivative-benfotiamine-from-diabetes-to-covid-19
#14
REVIEW
Kieran V Allowitz, John J Yoo, Justin R Taylor, Omar A Baloch, Kyra Harames, Kota V Ramana
Benfotiamine (S-benzoylthiamine-O-monophosphate), a unique, lipid-soluble derivative of thiamine, is the most potent allithiamine found in roasted garlic, as well as in other herbs of the genus Allium . In addition to potent antioxidative properties, benfotiamine has also been shown to be a strong anti-inflammatory agent with therapeutic significance to several pathological complications. Specifically, over the past decade or so, benfotiamine has been shown to prevent not only various secondary diabetic complications but also several inflammatory complications such as uveitis and endotoxemia...
June 2022: Future Medicinal Chemistry
https://read.qxmd.com/read/35115359/bond-study-a-randomised-double-blind-placebo-controlled-trial-over-12-months-to-assess-the-effects-of-benfotiamine-on-morphometric-neurophysiological-and-clinical-measures-in-patients-with-type-2-diabetes-with-symptomatic-polyneuropathy
#15
JOURNAL ARTICLE
Gidon J Bönhof, Gundega Sipola, Alexander Strom, Christian Herder, Klaus Strassburger, Birgit Knebel, Claudia Reule, Jan-Christoph Wollmann, Andrea Icks, Hadi Al-Hasani, Michael Roden, Oliver Kuss, Dan Ziegler
INTRODUCTION: Diabetic sensorimotor polyneuropathy (DSPN) affects approximately 30% of people with diabetes, while around half of cases are symptomatic. Currently, there are only few pathogenetically oriented pharmacotherapies for DSPN, one of which is benfotiamine, a prodrug of thiamine with a high bioavailability and favourable safety profile. While benfotiamine has shown positive effects in preclinical and short-term clinical studies, no long-term clinical trials are available to demonstrate disease-modifying effects on DSPN using a comprehensive set of disease-related endpoints...
February 3, 2022: BMJ Open
https://read.qxmd.com/read/34959619/effects-of-magnesium-orotate-benfotiamine-and-a-combination-of-vitamins-on-mitochondrial-and-cholinergic-function-in-the-tgf344-ad-rat-model-of-alzheimer-s-disease
#16
JOURNAL ARTICLE
Christian Viel, Adrian T Brandtner, Alexander Weißhaar, Alina Lehto, Marius Fuchs, Jochen Klein
Glucose hypometabolism, mitochondrial dysfunction, and cholinergic deficits have been reported in early stages of Alzheimer's disease (AD). Here, we examine these parameters in TgF344-AD rats, an Alzheimer model that carries amyloid precursor protein and presenilin-1 mutations, and of wild type F344 rats. In mitochondria isolated from rat hippocampi, we found reductions of complex I and oxidative phosphorylation in transgenic rats. Further impairments, also of complex II, were observed in aged (wild-type and transgenic) rats...
November 24, 2021: Pharmaceuticals
https://read.qxmd.com/read/34947984/serum-metabolomic-and-lipidomic-profiling-reveals-novel-biomarkers-of-efficacy-for-benfotiamine-in-alzheimer-s-disease
#17
JOURNAL ARTICLE
Ruchika Bhawal, Qin Fu, Elizabeth T Anderson, Gary E Gibson, Sheng Zhang
Serum metabolomics and lipidomics are powerful approaches for discovering unique biomarkers in various diseases and associated therapeutics and for revealing metabolic mechanisms of both. Treatment with Benfotiamine (BFT), a thiamine prodrug, for one year produced encouraging results for patients with mild cognitive impairment and mild Alzheimer's disease (AD). In this study, a parallel metabolomics and lipidomics approach was applied for the first exploratory investigation on the serum metabolome and lipidome of patients treated with BFT...
December 7, 2021: International Journal of Molecular Sciences
https://read.qxmd.com/read/34556698/role-of-pyruvate-in-maintaining-cell-viability-and-energy-production-under-high-glucose-conditions
#18
JOURNAL ARTICLE
Hideji Yako, Naoko Niimi, Ayako Kato, Shizuka Takaku, Yasuaki Tatsumi, Yasumasa Nishito, Koichi Kato, Kazunori Sango
Pyruvate functions as a key molecule in energy production and as an antioxidant. The efficacy of pyruvate supplementation in diabetic retinopathy and nephropathy has been shown in animal models; however, its significance in the functional maintenance of neurons and Schwann cells under diabetic conditions remains unknown. We observed rapid and extensive cell death under high-glucose (> 10 mM) and pyruvate-starved conditions. Exposure of Schwann cells to these conditions led to a significant decrease in glycolytic flux, mitochondrial respiration and ATP production, accompanied by enhanced collateral glycolysis pathways (e...
September 23, 2021: Scientific Reports
https://read.qxmd.com/read/34547367/screening-diagnosis-and-management-of-diabetic-sensorimotor-polyneuropathy-in-clinical-practice-international-expert-consensus-recommendations
#19
REVIEW
Dan Ziegler, Solomon Tesfaye, Vincenza Spallone, Irina Gurieva, Juma Al Kaabi, Boris Mankovsky, Emil Martinka, Gabriela Radulian, Khue Thy Nguyen, Alin O Stirban, Tsvetalina Tankova, Tamás Varkonyi, Roy Freeman, Péter Kempler, Andrew Jm Boulton
Diabetic sensorimotor polyneuropathy (DSPN) affects around one third of people with diabetes and accounts for considerable morbidity, increased risk of mortality, reduced quality of life, and increased health care costs resulting particularly from neuropathic pain and foot ulcers. Painful DSPN is encountered in 13-26% of diabetes patients, while up to 50% of patients with DSPN may be asymptomatic. Unfortunately, DSPN still remains inadequately diagnosed and treated. Herein we provide international expert consensus recommendations and algorithms for screening, diagnosis, and treatment of DSPN in clinical practice derived from a Delphi process...
April 2022: Diabetes Research and Clinical Practice
https://read.qxmd.com/read/34460928/novel-therapies-for-kidney-disease-in-people-with-diabetes
#20
JOURNAL ARTICLE
Nayana Khurana, Steven James, Melinda T Coughlan, Richard J MacIsaac, Elif I Ekinci
CONTEXT: The increasing burden of diabetic kidney disease (DKD) has led to the discovery of novel therapies. OBJECTIVE: This review aims to summarize the results of recent clinical trials that test the efficacy of potential therapies for DKD. METHODS: A systematized narrative review was performed utilizing the PubMed, Embase (Ovid), CINAHL, and Cochrane databases (January 2010 to January 2021). The included trials assessed the efficacy of specific medications using renal endpoints in adult participants with type 1 or 2 diabetes...
January 1, 2022: Journal of Clinical Endocrinology and Metabolism
keyword
keyword
36729
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.